insights_auto
Why is MVIR up 5.77%?
Dive Deeperchevron_right
MVIR:STO
Medivir AB
SEKÂ 1.69
arrow_upward
+5.77%(+0.092) 1D
Oct 2, 5:29:51 PM GMT+2 · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for MVIR...
Open
SEKÂ 1.71
High
SEKÂ 1.78
Low
SEKÂ 1.67
Mkt. cap
1.05B
Avg. vol.
1.88M
Volume
2.72M
52-wk high
SEKÂ 2.88
52-wk low
SEKÂ 0.34
EPS
-SEKÂ 0.37
Shares outstanding
624.18M
No. of employees
6
Open
SEKÂ 1.71
High
SEKÂ 1.78
Low
SEKÂ 1.67
Mkt. cap
1.05B
Avg. vol.
1.88M
Volume
2.72M
52-wk high
SEKÂ 2.88
52-wk low
SEKÂ 0.34
EPS
-SEKÂ 0.37
Shares outstanding
624.18M
No. of employees
6
News stories
From web sources and news partners
The Motley Fool
·
51 minutes ago
History Says Coca-Cola Stock Holds Up When the S&P 500 Falls
U.S. Global Investors
·
1 day ago
Gold Stumbled in September, but Gold Miners Beat Every Sector in the S&P 500
TradingView
·
5 hours ago
Energy sector outperforms S&P 500 in Q3 as oil prices rise
Profile
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
About Medivir AB